Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis

  • CE-Systematic reviews and meta-analysis
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

To evaluate the efficacy and safety of colchicine for secondary prevention of coronary heart disease (CHD), relevant randomized controlled trials (RCTs) were identified by searching several databases from the creation date to August 31, 2020 and were reviewed. Eight eligible trials of colchicine therapy involving a total of 11, 463 patients were included (5, 776 subjects received colchicine, while 5, 687 subjects were in the respective control arms), and the outcome was reported as risk ratio (RR) and 95% confidence interval (CI), as the relative measure of association. Overall, the incidences of major adverse cardiovascular events (MACEs) (RR 0.70; 95% CI 0.61–0.80), myocardial infarction (MI) (RR 0.77; 95% CI 0.64–0.94), emergency readmission due to CHD (RR 0.70; 95% CI 0.58–0.86), and ischemic stroke (RR 0.49; 95% CI 0.30–0.79) were lower in the colchicine group than in the placebo arm. We did not find a significant reduction in the incidence of all-cause mortality (RR 1.03; 95% CI 0.80–1.32). Although the incidence of diarrhea in the colchicine treatment group was higher than that in the placebo arms (RR 2.53; 95% CI 1.17, 5.48), the symptoms disappeared rapidly after drug withdrawal, and no serious adverse reactions occurred. In summary, colchicine is an accessible, safe, and effective drug that could be successfully utilized for the secondary prevention of CHD. The tolerability and benefits should be confirmed in in-depth clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

CHD:

Coronary heart disease

RCTs:

Relevant randomized controlled trials

MACEs:

Major adverse cardiovascular events

MI:

Myocardial infarction

CI:

Confidence interval

RR:

Risk ratio

ACS:

Acute coronary syndrome

FMF:

Familial mediterranean fever

AMI:

Acute myocardial infarction

AF:

Atrial fibrillation

PCI:

Percutaneous coronary intervention

hsCRP:

High-sensitivity C-reactive protein

STEMI:

ST-segment elevation myocardial infarction

References

  1. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude OT, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800. https://doi.org/10.1056/NEJMoa1500857

    Article  PubMed  Google Scholar 

  2. Kasikara C, Doran AC, Cai B, Tabas I (2018) The role of non-resolving inflammation in atherosclerosis. J Clin Invest 128:2713–2723. https://doi.org/10.1172/JCI97950

    Article  PubMed  PubMed Central  Google Scholar 

  3. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE (2002) Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106:2894–2900. https://doi.org/10.1161/01.cir.0000042674.89762.20

    Article  PubMed  Google Scholar 

  4. Vergallo R, Crea F (2020) Atherosclerotic plaque healing. N Engl J Med 383:846–857. https://doi.org/10.1056/NEJMra2000317

    Article  CAS  PubMed  Google Scholar 

  5. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AJ, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2008) Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 359:2195–2207. https://doi.org/10.1056/NEJMoa0807646

    Article  CAS  PubMed  Google Scholar 

  6. O’Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA (2016) Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 315:1591–1599. https://doi.org/10.1001/jama.2016.3609

    Article  CAS  PubMed  Google Scholar 

  7. O’Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, Steen DL (2014) Effect of darapladib on major coronary events after an acute coronary syndrome: the solidtimi 52 randomized clinical trial. JAMA 312:1006–1015. https://doi.org/10.1001/jama.2014.11061

    Article  CAS  PubMed  Google Scholar 

  8. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ (2019) Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380:752–762. https://doi.org/10.1056/NEJMoa1809798

    Article  CAS  PubMed  Google Scholar 

  9. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Cantos TG, Sahlgrenska A, Institute OM, GöteborgsGothenburgSahlgrenskaInstitutionen UUAFM (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England J Med 377:1119–1131. https://doi.org/10.1056/NEJMoa1707914

    Article  CAS  Google Scholar 

  10. Nuki G (2008) Colchicine: its mechanism of action and efficacy in crystal-induced inflam-mation. Curr Rheumatol Rep 10:218–227. https://doi.org/10.1007/s11926-008-0036-3

    Article  CAS  PubMed  Google Scholar 

  11. Nguyen MT, Fernando S, Schwarz N, Tan JT, Bursill CA, Psaltis PJ (2019) Inflammation as a therapeutic target in atherosclerosis. J Clin Med. https://doi.org/10.3390/jcm8081109

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428:198–202. https://doi.org/10.1038/nature02393

    Article  CAS  PubMed  Google Scholar 

  13. Cimmino G, Tarallo R, Conte S, Morello A, Pellegrino G, Loffredo FS, Cali G, De Luca N, Golino P, Trimarco B, Cirillo P (2018) Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and lim domain kinase 1. Vascul Pharmacol 111:62–70. https://doi.org/10.1016/j.vph.2018.09.004

    Article  CAS  PubMed  Google Scholar 

  14. Cirillo P, Taglialatela V, Pellegrino G, Morello A, Conte S, Di Serafino L, Cimmino G (2020) Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Thromb Thrombolysis 50:468–472. https://doi.org/10.1007/s11239-020-02121-8

    Article  CAS  PubMed  Google Scholar 

  15. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R (2005) Pharmacological and clinical basis of treatment of familial mediterranean fever (fmf) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 4:17–24. https://doi.org/10.2174/1568010053622984

    Article  Google Scholar 

  16. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, Belli R, Trinchero R (2005) Colchicine in addition to conventional therapy for acute pericarditis: results of the colchicine for acute pericarditis (cope) trial. Circulation 112:2012–2016. https://doi.org/10.1161/circulationaha.105.542738

    Article  CAS  PubMed  Google Scholar 

  17. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, Demarie D, Ferro S, Forno D, Maestroni S, Cumetti D, Varbella F, Trinchero R, Spodick DH, Adler Y (2014) Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (corp-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 383:2232–2237. https://doi.org/10.1016/S0140-6736(13)62709-9

    Article  CAS  PubMed  Google Scholar 

  18. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Cochrane handbook for systematic reviews of interventions version 6.0 (updated july 2019). Cochrane www.training.cochrane.org/handbook

  19. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu X, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings MMW, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL (2020) Colchicine in patients with chronic coronary disease. New Engl J Med 383:1838–1847. https://doi.org/10.1056/NEJMoa2021372

    Article  CAS  PubMed  Google Scholar 

  20. Tardif J, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie M, Dubé M, Rhainds D, Provencher M, Blondeau L, Allier OAL, PL, Guertin M, Roubille F, (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381:2497–2505. https://doi.org/10.1056/NEJMoa1912388

    Article  CAS  PubMed  Google Scholar 

  21. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013) Low-dose colchicine for secondary prevention of CVD. J Am Coll Cardiol 61:404–410. https://doi.org/10.1016/j.jacc.2012.10.027

    Article  CAS  PubMed  Google Scholar 

  22. O’Keefe JH, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO (1992) Ineffectiveness of coichicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 19:1597–1600. https://doi.org/10.1016/0735-1097(92)90624-v

    Article  PubMed  Google Scholar 

  23. Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, Driva M, Hahalis G, Pyrgakis V, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW (2013) Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol 61:1679–1685. https://doi.org/10.1016/j.jacc.2013.01.055

    Article  CAS  PubMed  Google Scholar 

  24. Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V, Cleman MW, Manolis AS, Tousoulis D, Lekakis J (2015) Anti-inflammatory treatment with colchicine in acute myocardial infarction. Circulation 132:1395–1403. https://doi.org/10.1161/circulationaha.115.017611

    Article  CAS  PubMed  Google Scholar 

  25. Akodad M, Lattuca B, Nagot N, Georgescu V, Buisson M, Cristol J, Leclercq F, Macia J, Gervasoni R, Cung T, Cade S, Cransac F, Labour J, Dupuy A, Roubille F (2017) Colin trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Arch Cardiovasc Dis 110:395–402. https://doi.org/10.1016/j.acvd.2016.10.004

    Article  PubMed  Google Scholar 

  26. Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW (2012) Effect of colchicine compared with placebo on high sensitivity c-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolys 33:88–94. https://doi.org/10.1007/s11239-011-0637-y

    Article  CAS  Google Scholar 

  27. Solomon DH, Liu C, Kuo I, Zak A, Kim SC (2016) Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with medicare claims. Ann Rheum Dis 75:1674–1679. https://doi.org/10.1136/annrheumdis-2015-207984

    Article  CAS  PubMed  Google Scholar 

  28. Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M (2016) Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev D11047. https://doi.org/10.1002/14651858.CD011047.pub2

    Article  Google Scholar 

  29. Al-Abdouh A, Barbarawi M, Khan SU, Osman M, Upadhrasta S, Solipuram V, Abusnina W, Radaideh Q, Zhao D, Michos ED (2020) Colchicine therapy in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Coron Artery Dis. https://doi.org/10.1097/MCA.0000000000000931

    Article  PubMed  Google Scholar 

  30. Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, Hasan AA, Amar S (2018) Inflammation, immunity, and infection in atherothrombosis: jacc review topic of the week. J Am Coll Cardiol 72:2071–2081. https://doi.org/10.1016/j.jacc.2018.08.1043

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Xiang Z, Yang J (2020) The therapeutic potential of miR-135b in MI: anti-inflammatory trials may be enlightening. Int J Cardiol 312:99. https://doi.org/10.1016/j.ijcard.2020.03.030

    Article  PubMed  Google Scholar 

  32. Imazio M, Andreis A, Brucato A, Adler Y, De Ferrari GM (2020) Colchicine for acute and chronic coronary syndromes. Heart. https://doi.org/10.1136/heartjnl-2020-317108

    Article  PubMed  Google Scholar 

  33. Fiolet A, Nidorf SM, Mosterd A, Cornel JH (2019) Colchicine in stable coronary artery disease. Clin Ther 41:30–40. https://doi.org/10.1016/j.clinthera.2018.09.011

    Article  CAS  PubMed  Google Scholar 

  34. Dalbeth N, Lauterio TJ, Wolfe HR (2014) Mechanism of action of colchicine in the treatment of gout. Clin Ther 36:1465–1479. https://doi.org/10.1016/j.clinthera.2014.07.017

    Article  CAS  PubMed  Google Scholar 

  35. Bhattacharyya B, Pana D, Gupta S, Banerjee M (2008) Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 28:155–183. https://doi.org/10.1002/med.20097

    Article  CAS  PubMed  Google Scholar 

  36. Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P (2014) Novel therapeutics for the treatment of familial mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther 95:89–97. https://doi.org/10.1038/clpt.2013.148

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (81770360), Hubei Province Health and Family Planning Scientific Research Project (WJ2019Z004), Hubei Provincial Natural Science Foundation of China (2018CFA044), and Hubei Province’s Outstanding Medical Academic Leader program.

Author information

Authors and Affiliations

  1. The first People’s Hospital of Yichang, The People’s Hospital of China, Three Gorges University, Yichang, 443000, Hubei, China

    Zujin Xiang, Jian Yang, Liu Di, Cong Ma, Jingyi Wu & Yifan Huang

  2. The First Clinical Medical College of China, Institute of Cardiovascular Diseases, Three Gorges University, Yichang, 443000, Hubei, China

    Jun Yang, Jing Zhang, Zhixing Fan & Chaojun Yang

Authors
  1. Zujin Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhixing Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chaojun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Liu Di
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jingyi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yifan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian Yang.

Ethics declarations

Conflict of interest

All authors declare that the article has not been previously published elsewhere and is not under consideration for publication in another journal. All authors consent to the publication of the article in its actual form.

Statement of human and animal rights

Patients were not directly involved in the study, and data were obtained from published trials.

Informed consent

No informed consent is required for this type of study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiang, Z., Yang, J., Yang, J. et al. Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis. Intern Emerg Med 16, 487–496 (2021). https://doi.org/10.1007/s11739-020-02606-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-020-02606-7

Keywords

Search

Navigation